Press release
Hematological Malignancies Drugs Market in 2024 Detailed Study Analysis
According to the latest market research, the global hematological malignancies drugs market is valued at US$ 13.76 Billion in 2021, and it is expected to reach US$ 42.78 Billion by 2030, with a CAGR of 13.7 % during the forecast period of 2022-2030.
Request for Sample Pages:
https://www.insightaceanalytic.com/request-sample/1211
Haematological malignancies impact blood, bone marrow, and lymph nodes. The three forms of haematological malignancies are myeloma, leukaemia, and lymphoma, the most common blood cancer. Among the emerging targeted therapies that have improved clinical outcomes for blood malignancies are small molecule inhibitors, monoclonal antibodies, bispecific T cell engagers, antibody-drug conjugates, recombinant immunotoxins, and Chimeric Antigen Receptor T (CAR-T) cells.
The growth of the Hematological Malignancies Drugs Market can be attributed to factors such as the rising prevalence of blood malignancies, rising healthcare expenditure, increasing R&D activities to develop novel cancer therapies, adoption of precision medicine in the field of haematological malignancies, increasing number of drug approvals for treating various types of haematological malignancies, and rising innovations in leukemia and lymphoma targeted therapies. Blood Cancer Statistics 2021 predicts that approximately 459,058 cases of leukaemia and more than 962,304 lymphoma cases will be diagnosed in the United States. In addition, according to Leukemia & Lymphoma Society 2020, approximately 85,720 new lymphoma cases will be diagnosed in the United States in 2020. In addition, the newly reported lymphoma cases include 8,480 Hodgkin and 77,240 cases of Non-Hodgkin Lymphoma. Thus, it is anticipated that the rising incidences of leukaemia and lymphoma will increase demand for this market shortly.
However, it is anticipated that the high cost of treatment and products, adverse effects of therapeutics, unfavourable medical reimbursement policies, and safety concerns will limit market growth in the coming years.
Enquiry Before Buying:
https://www.insightaceanalytic.com/enquiry-before-buying/1211
Regionally, North America is projected to generate the highest CAGR in this market over the forecast period due to the rising R&D activities in cancer research. The Asia Pacific region also majorly contributes to the growth of the Hematological Malignancies Drugs Market. The increasing cancer research funding, high prevalence of blood malignancies, and the rising need for effective therapies contribute to the market growth.
Major market players operating in the hematological malignancies drugs market include AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Immune-Onc Therapeutics, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, among others.
Key developments in the market:
• In October 2021, Novartis acquired the US FDA approval for Scemblix (asciminib) to treat chronic myeloid leukemia (CML) in two distinct indications.
• In September 2021, AbbVie and Genmab A/S published the results of the dose-escalation part of the Phase 1/2 EPCORE NHL-1 first-in-human (FIH) dose-escalation and cohort expansion clinical trial eValueating the safety and preliminary efficacy of the investigational therapy epcoritamab (DuoBody-CD3xCD20) in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL).
• In March 2021, Sanofi SA received the US FDA approval for Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
• In August 2020, GlaxoSmithKline plc received US FDA approval for BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for patients with relapsed or refractory multiple myeloma.
• In July 2020, Takeda Pharmaceutical Co. Ltd. received US FDA approval for pevonedistat, an investigational cancer drug for treating higher-risk myelodysplastic syndromes.
Get Specific Chapter/Information From The Report:
https://www.insightaceanalytic.com/customisation/1211
Market Segments
Global Hematological Malignancies Drugs Market, by Drugs, 2022-2030 (Value US$ Mn)
• Monoclonal Antibodies
o Blincyto (Blinatumomab)
o Besponsa (Inotuzumab Ozogamicin)
o Lumoxiti (Moxetumomab Pasudotox)
o Mylotarg (Gemtuzumab Ozogamicin)
o Opdivo (Nivolumab)
o AiRuiKa (Camrelizumab)
o Tyvyt (Sintilimab)
o Tislelizumab
o Gazyva (Obinutuzumab)
o Zynlonta (Loncastuximab Tesirine-lpyl)
o Darzalex (Daratumumab)
o Blenrep (Belantamab Mafodotin-blmf)
o Keytruda (Pembrolizumab)
o Adcetris (Brentuximab Vedotin)
o Arzerra (Ofatumumab
• CAR-T Cell Therapy
o Tecartus (Brexucabtagene Autoleucel)
o Kymriah (Tisagenlecleucel)
o Yescarta (Axicabtagene Ciloleucel)
o Breyanzi (Lisocabtagene Maraleucel)
o Abecma (Idecabtagene Vicleucel)
Global Hematological Malignancies Drugs Market, by Pipeline Products, 2022-2030 (Value US$ Mn)
• Monoclonal Antibodies
o Teclistamab
o Iomab-B
o Ublituximab
o CS1001
• CAR-T Cell Therapy
o Ciltacabtagene Autoleucel (JNJ-68284528)
Global Hematological Malignancies Drugs Market, by Indications, 2022-2030 (Value US$ Mn)
• Leukemia
o Acute Lymphoblastic Leukemia
o Chronic Lymphoblastic Leukemia
o Acute Myeloid Leukemia
• Lymphoma
o Hodgkin's Lymphoma
o Non-Hodgkin's Lymphoma
• Multiple Myeloma
Global Hematological Malignancies Drugs Market, by region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Hematological Malignancies Drugs Market, by Country, 2022-2030 (Value US$ Mn)
• The U.S.
• Canada
Europe Hematological Malignancies Drugs Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Hematological Malignancies Drugs Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Hematological Malignancies Drugs Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Hematological Malignancies Drugs Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa
Why should buy this report:
To receive a comprehensive analysis of clinical trial/pipeline products for the global hematological malignancies drugs market
To receive a market overview and future trends of the hematological malignancies drugs market
To analyze the hematological malignancies drugs market drivers and challenges
To get information on the Hematological Malignancies Drugs Market size (Value US$ Mn) forecast to 2030
Major investments, mergers & acquisitions in the Hematological Malignancies Drugs Market industry
Get more information: @
https://www.insightaceanalytic.com/report/global-hematological-malignancies-drugs-market--/1211
Contact us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.JPG
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hematological Malignancies Drugs Market in 2024 Detailed Study Analysis here
News-ID: 3878059 • Views: …
More Releases from Insightace Analytic Pvt Ltd.
Prochlorperazine Maleate Market Size, Share and Trends Analysis Report 2025-2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Prochlorperazine Maleate Market- (By Indication (Nausea and Vomiting Management, Vertigo, Mental Health Disorders (e.g., Schizophrenia)), By Dosage Form (Oral Tablets, Rectal Suppositories, Injectable Formulations), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-User (Hospitals, Clinics, Ambulatory Surgical Centers, Homecare Settings)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research…
Primary Cells Market Survey Detailed Analysis and Forecast 2025-2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Primary Cells Market- (By Type (Hematopoietic, Dermatocytes, Hepatocytes, Gastrointestinal, Lung, Renal, Heart, Musculoskeletal), Origin (Human Primary Cells, Animal Primary Cells), End User (Life Science Research Companies, Research Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic, the Global Primary Cells Market Size is valued at USD…
Predictive Disease Analytics Market expected to Witness Huge Revenue Growth to 2 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Predictive Disease Analytics Market Size, Share & Trends Analysis Report By Component (Hardware, Software & Services), By Deployment (On-premise and Cloud-based), By End-user (Healthcare Providers, Healthcare Payers)- Market Outlook And Industry Analysis 2034"
The Global Predictive Disease Analytics Market is estimated to reach over USD 22.6 Bn by 2034, exhibiting a CAGR of 21.2% during…
Predictive Biomarkers Market Current Scenario with Future Trends Analysis to 203 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Predictive Biomarkers Market- (By Indication (Cancer, Neurological Disorder, Cardiovascular Disorder, Immunological Disorder, Others), By End-Use (Diagnostic Centers, Contract Research Organizations (CROs), Academic Research Institutes, Pharma & Biotech Companies, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic, the Global Predictive Biomarkers Market is expected to grow with…
More Releases for Drugs
Generic Drugs Market Application Anti-Infective Drugs, Anti-Arthritis Drugs, Ant …
Generic drugs are the medications that are developed to be similar to a medicine that is already commercially available in the market with a brand name. The generic drug is similar to the medicine available in terms of dosage, safety and strength, mode of administration, quality and intended use. Due to the similarities, generic drugs are capable of treating various diseases. Generic drugs are most cost effective than the branded…
Cytotoxic Drugs Market Growing Demand for Antimetabolite Drugs
According to Precision Business Insights (PBI), the latest report, the cytotoxic drugs market is expected to be valued at USD 15,927.2 million in 2022 and is poised to grow at a significant CAGR of 2.2% over 2022-2028. The primary drivers of the expansion of the global cytotoxic drugs market include the increasing prevalence of cancer diseases, the increasing use and approval of cytotoxic drugs, and the increasing consumption of alcohol…
Global Antithrombotic Drugs Market | Global Antithrombotic Drugs Industry | Glob …
Antithrombotic drugs are special drugs that help to prevent the formation of thrombus or clot. These drugs are used to reduce the formation of blood clots by reducing the capability of body to form a blood clot. Antithrombotic drugs act by preventing the production of vitamin K in the liver. Anticoagulant, antiplatelet, and thrombolytic agents are different types of antithrombotic agents that act by different clotting processes. Arterial & venous…
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication…
Hepatitis Drugs Market by Therapeutics, Diagnostics, Patient, Drugs Policy
The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market.
Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/hepatitis-drugs-market
Among the various types, the hepatitis C segment is expected to be the largest segment, and expected to witness the fastest…
Epilepsy Drugs Market by Country, Drugs, Company & Forecast
For More Information:
https://renub-research.blogspot.com/2019/04/the-factors-that-are-driving-global.html
Epilepsy is a chronic disease in which patient’s brain activities become abnormal due to seizures. Seizure is an unexpected rush of electrical activity in the brain. Seizure is categorized by two types - generalized seizures and focal or partial seizures. Generalized seizures affect the whole brain whereas focal or partial seizures affect just one part of the brain. Global epilepsy drugs market is expected to cross US$…
